Blood products - Revision history

Rossdonaldson1: /* Types */

2022-05-14T10:49:13Z

Types

← Older revision		Revision as of 10:49, 14 May 2022
Line 10:		Line 10:
	*[[Humate-P]]		*[[Humate-P]]
	*[[Prothrombin complex concentrates]]		*[[Prothrombin complex concentrates]]
	*[[~~Fresh whole~~ blood]]		*[[Whole blood]]

	==Unit Conversions==		==Unit Conversions==

Rossdonaldson1: /* Types */

2022-05-14T10:48:09Z

Types

← Older revision		Revision as of 10:48, 14 May 2022
Line 10:		Line 10:
	*[[Humate-P]]		*[[Humate-P]]
	*[[Prothrombin complex concentrates]]		*[[Prothrombin complex concentrates]]
			*[[Fresh whole blood]]

	==Unit Conversions==		==Unit Conversions==

Rossdonaldson1: /* Special Considerations */

2018-09-23T17:59:30Z

Special Considerations

@@ Line 15: / Line 15: @@
 ==Special Considerations==
-===Leukocyte Irradiated/Depleted RBCs<ref>Treleaven J et al. Guidelines on the use of irradiated blood components: Prepared by the BCSH Blood Transfusion Task Force. British Society for Haematology. Jan 2013. http://www.bcshguidelines.com/documents/irrad_bcsh_072010.pdf</ref>===
+{{Leukocyte Irradiated and Reduced (Depleted) Blood Products}}
 ==See Also==

Rossdonaldson1: /* Products */

2017-11-23T13:03:36Z

Products

← Older revision		Revision as of 13:03, 23 November 2017
Line 11:		Line 11:
	*[[Prothrombin complex concentrates]]		*[[Prothrombin complex concentrates]]

			==Unit Conversions==
	{{Blood product unit conversions}}		{{Blood product unit conversions}}

Rossdonaldson1 at 12:31, 23 November 2017

2017-11-23T12:31:56Z

← Older revision		Revision as of 12:31, 23 November 2017
Line 1:		Line 1:
	==Background==		==Background==
			{{Transfusion risk}}

			==Products==
	===Types===		===Types===
	*[[Packed red blood cells]]		*[[Packed red blood cells]]
Line 7:		Line 10:
	*[[Humate-P]]		*[[Humate-P]]
	*[[Prothrombin complex concentrates]]		*[[Prothrombin complex concentrates]]
	{{~~Transfusion risk~~}}
			{{Blood product unit conversions}}

			==Special Considerations==
	===Leukocyte Irradiated/Depleted RBCs<ref>Treleaven J et al. Guidelines on the use of irradiated blood components: Prepared by the BCSH Blood Transfusion Task Force. British Society for Haematology. Jan 2013. http://www.bcshguidelines.com/documents/irrad_bcsh_072010.pdf</ref>===		===Leukocyte Irradiated/Depleted RBCs<ref>Treleaven J et al. Guidelines on the use of irradiated blood components: Prepared by the BCSH Blood Transfusion Task Force. British Society for Haematology. Jan 2013. http://www.bcshguidelines.com/documents/irrad_bcsh_072010.pdf</ref>===
	*Gamma or X-radiated blood components to prevent [[Transfusion-associated graft-versus-host disease]] for at risk patients		*Gamma or X-radiated blood components to prevent [[Transfusion-associated graft-versus-host disease]] for at risk patients
Line 42:		Line 48:
	**Hematologic malignancies other than Hodgkin lymphoma		**Hematologic malignancies other than Hodgkin lymphoma
	**Solid tumors treated with cytotoxic agents		**Solid tumors treated with cytotoxic agents

	=====Indications For Leukoreduced Blood Products<ref>The reintroduction of nonleukoreduced blood: would patients and clinicians agree? Rosenbaum L, Tomasulo P, Lipton KS, Ness P. Transfusion. 2011 Dec;51(12):2739-43. Epub 2011 May 26.</ref>=====		=====Indications For Leukoreduced Blood Products<ref>The reintroduction of nonleukoreduced blood: would patients and clinicians agree? Rosenbaum L, Tomasulo P, Lipton KS, Ness P. Transfusion. 2011 Dec;51(12):2739-43. Epub 2011 May 26.</ref>=====
	*Chronically transfused		*Chronically transfused
Line 55:		Line 62:
	*Routine solid organ transplant		*Routine solid organ transplant
	*Routine infant cardiac surgery		*Routine infant cardiac surgery

	~~{{Blood product unit conversions}}~~

	==See Also==		==See Also==

Kxl328 at 21:05, 23 September 2016

2016-09-23T21:05:37Z

← Older revision		Revision as of 21:05, 23 September 2016
Line 42:		Line 42:
	**Hematologic malignancies other than Hodgkin lymphoma		**Hematologic malignancies other than Hodgkin lymphoma
	**Solid tumors treated with cytotoxic agents		**Solid tumors treated with cytotoxic agents
			=====Indications For Leukoreduced Blood Products<ref>The reintroduction of nonleukoreduced blood: would patients and clinicians agree? Rosenbaum L, Tomasulo P, Lipton KS, Ness P. Transfusion. 2011 Dec;51(12):2739-43. Epub 2011 May 26.</ref>=====
			*Chronically transfused
			*Cardiac surgery
			*Solid organ or stem cell transplant recipients, before and after
			*Previous febrile nonhemolytic transfusion reactions
			*CMV seronegative patients at risk

	====Not Routinely Needing Irradiated Products====		====Not Routinely Needing Irradiated Products====

Kxl328 at 21:02, 23 September 2016

2016-09-23T21:02:58Z

← Older revision		Revision as of 21:02, 23 September 2016
Line 20:		Line 20:
	*Those products not used for intended recipient may be returned safely to stock for others not requiring irradiated components, though with reduced shelf life		*Those products not used for intended recipient may be returned safely to stock for others not requiring irradiated components, though with reduced shelf life
	*Not necessary to irradiate FFP, cryoprecipitate, fractioned plasma products		*Not necessary to irradiate FFP, cryoprecipitate, fractioned plasma products
	====~~At Risk Patients Requiring~~ Irradiated Products====		=====Generally Accepted Indications For Irradiated Blood Products<ref>Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, Saran F, Thurston J, Webb D. Br J Haematol. 2011;152(1):35.</ref><ref>2.AABB Technical Manual, 17th ed, Roback JD, Grossman BJ, Harris T, et al, (Eds). American Association of Blood Banks Press, Bethesda 2011. p.755.</ref>=====
	*~~Congenital immunodeficiency syndromes (T-~~cell ~~deficiencies)~~		*Immunocompromised stem cell recipients
	*~~Neonates, especially if premature~~		*Organ transplant recipients
	*~~Exchange~~ transfusions ~~in pre-term~~ and ~~term infants~~		*Patients undergoing marrow transplantation
	*~~Intrauterine transfusions~~		*Intrauterine transfusion
			*Neonatal exchange transfusions
			*Premature and low birthweight neonates
			*Hodgkin lymphoma
			*Congenital cell-mediated immunodeficiencies (DiGeorge, Wiskott-Aldrich, Leiner's, 5'-nucelotidase deficiency)
	*Acquired immunodeficiencies to include:		*Acquired immunodeficiencies to include:
	**Lymphoma		**Leukemia, CLL
	**Leukemia
	**Aplastic anemia		**Aplastic anemia
	**Neutropenia		**Neutropenia
	*Patients receiving:		*Patients receiving:
	**Stem cell transplants or harvesting
	**Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)		**Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)
	**Certain biologic immunosuppresants (alemtuzumab)		**Certain biologic immunosuppresants (alemtuzumab)
			*Donations from biologic relatives
			*Donations from HLA-matched donors
			*Genetically homogenous populations
			*Probably indicated int:
			**Hematologic malignancies other than Hodgkin lymphoma
			**Solid tumors treated with cytotoxic agents

	====Not Routinely Needing Irradiated Products====		====Not Routinely Needing Irradiated Products====

Mholtz at 00:32, 8 September 2016

2016-09-08T00:32:24Z

← Older revision		Revision as of 00:32, 8 September 2016
Line 45:		Line 45:

	==See Also==		==See Also==
	~~{{Transfusion reactions see also}}~~		*[[Acute transfusion reaction]]
	*[[~~Transfusion-associated graft-versus-host disease~~]]		*[[Massive transfusion]]
	*[[~~Massive_Transfusion_Protocol\|~~Massive ~~Transfusion Protocol~~]]		*[[Coagulopathy (main)]]
	*[[Coagulopathy (~~Main~~)]]		*[[Tranexamic acid]]
	*[[~~TXA~~]]

	==References==		==References==
	<references/>		<references/>

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Heme/Onc]]		[[Category:Heme/Onc]]

Rossdonaldson1: /* See Also */

2016-09-07T20:13:32Z

Kxl328 at 01:46, 20 August 2016

2016-08-20T01:46:05Z

← Older revision		Revision as of 01:46, 20 August 2016
Line 31:		Line 31:
	**Neutropenia		**Neutropenia
	*Patients receiving:		*Patients receiving:
	*Stem cell transplants or harvesting		**Stem cell transplants or harvesting
	**Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)		**Purine analogue chemotherapies (fludarabine, cladribine, deoxycoformicin, bendamustine, clofarabine, etc.)
	**Certain biologic immunosuppresants (alemtuzumab)		**Certain biologic immunosuppresants (alemtuzumab)

	====Not Routinely Needing Irradiated Products====		====Not Routinely Needing Irradiated Products====
	*HIV, AIDS		*HIV, AIDS

← Older revision		Revision as of 20:13, 7 September 2016
Line 41:		Line 41:
	*Routine solid organ transplant		*Routine solid organ transplant
	*Routine infant cardiac surgery		*Routine infant cardiac surgery

			{{Blood product unit conversions}}

	==See Also==		==See Also==